Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. immunogrow

ImmunoGrow

Making life-saving cancer therapies more widely available by simplifying production processes, reducing costs and enhancing patient safety through its patent-protected biomimicking mesh material.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 ImmunoGrow project word cloud

Explore the words cloud of the ImmunoGrow project. It provides you a very rough idea of what is the project "ImmunoGrow" about.

gold    grey    500    prohibitive    treatments    initial    changing    fund    release    labour    untreatable    83    sickest    technologies    seed    patients    cleanroom    expects    2019    poor    seeking    conduct    priced    cancers    market    manufacturers    car    business    protected    2021    immunogrow    cancer    475    standard    helps    lab    15    anticipated    significantly    lifesaving    produces    core    closed    infrastructure    structure    activation    reducing    cell    patient    costly    rates    prices    q3    operator    customers    ltd    tests    harness    cells    treatment    input    engineered    addressable    natural    genetically    8x    life    save    body    limitations    capture    skilled    round    limited    individualised    achieves    publically    aggressive    requirement    feasibility    expensive    unless    consumables    dynabeads    plan    variability    automated    trials    struggling    reduce    healthcare    remission    patent    2030    yield    mimics    manufacture    safer    independent    citizens    full    shown    simplifying    gmt    encounter    mesh    cheaper    therapies    ing    solutions    performance    immune    600mn   

Project "ImmunoGrow" data sheet

The following table provides information about the project.

Coordinator		 Grey Matter Technologies Limited 

Organization address
address: MERTON BREE ENNISCORTHY
city: WEXFORD
postcode: Y21 Y5V0
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Ireland [IE]
 Project website http://www.immunogrow.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2019-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    Grey Matter Technologies Limited IE (WEXFORD) coordinator 50˙000.00

Map

 Project objective

Lifesaving cell-based CAR-T therapies have achieved remission rates of up to 83% for patients with the most aggressive and untreatable cancers. These therapies harness a patient’s own genetically engineered immune cells to target cancer cells. However, manufacturers are struggling to produce these individualised treatments at scale resulting in prohibitive prices as high as $475,000 per treatment. Unless solutions that address these limitations are provided, publically-funded EU healthcare systems & citizens will be priced out of these life-changing therapies.

The challenges they face include poor cell growth performance due to patient sample variability, limitations associated with equipment adopted from the research lab that require costly skilled labour, costly consumables and expensive cleanroom infrastructure.

Compared to the gold standard, Dynabeads, initial testing has shown that the ImmunoGrow technology produces an 8x higher cell yield which helps to save the sickest patients who have limited cells and significantly reduce the cost to manufacture these therapies by simplifying the process, reducing the requirement for skilled operator input and making this step both ‘closed’ and automated. ImmunoGrow achieves this through its patent-protected mesh structure that mimics the natural growth conditions cells encounter in the body.

Grey Matter Technologies (‘GMT’) Ltd. is seeking support to help fund trials with two identified customers as well to help it to conduct an independent set of tests on the product’s performance. Both these trials, as well as an associated business plan or feasibility study, will be core to the raising of a seed round of €500,000 in 2019 to further develop the technology with the release of a full-scale product anticipated for Q3 2021. GMT expects to capture 15% of the $600mn addressable T-Cell Activation market in 2030. In doing so, it will make these life changing treatments cheaper, safer and more widely available.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNOGROW" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUNOGROW" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Woodywood pickering (2019)

Bio-based (fully renewable) cost effective Polymer for new generation of ecological Coatings leveraging a disruptive innovation in the use of Pickering emulsion.

Read More  

MACCO (2019)

Bring social robots into reality with the first real world leading bartender (MACCO)

Read More  

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More